Get In Touch
Have any questions or comments about the content you see on this page?
Our News
September 10, 2020
Alnylam’s Brendan Martin, Head of Europe, Middle East, Africa, and Canada and General Manager for the UK & Ireland, recently spoke with Dominic Tyer on the Pharmaphorum podcast about a broad range of topics including the state of the UK biotechnology industry, lessons learned during the COVID-19 pandemic, and what it means to be leader in the life sciences in 2020. Brendan also explained how RNAi (RNA interference) therapeutics silence genes and why we believe RNAi has the potential to yield new treatment options to combat SARS-CoV-2, the virus that causes COVID-19, and other coronaviruses.
Perspectives, Podcasts, RNAi, Brendan Martin, Executive Team, COVID-19
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site